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Abstract
Twin-studies suggest that a significant portion of individual differences in the propensity to take risks resides in people’s
genetic make-up and there is evidence that variability in dopaminergic systems relates to individual differences in risky
choice. We examined the link between risk taking in a risk taking task (the Balloon Analogue Risk Task, BART) and a variable
number tandem repeat (VNTR) polymorphism in the 39UTR of the dopamine transporter gene (SLC6A3/DAT1). Behavior in
BART is known to be associated with activity in striatal reward-processing regions, and DAT1 is assumed to modulate striatal
dopamine levels. We find that carriers of DAT1 alleles, which presumably result in lower striatal dopamine availability,
showed more risk taking, relative to carriers of the alleles associated with higher striatal dopamine availability. Our analyses
suggest that the mechanism underlying this association is diminished sensitivity to rewards among those who take more
risks. Overall, our results support the notion that a behavioral genetic approach can be helpful in uncovering the basis of
individual differences in risk taking.
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Introduction
A significant portion of individual differences in financial
decision-making and risk-taking behavior can be attributed to
genetic differences between individuals. This result is suggested by
a number of twin-studies, with heritability estimates regarding
behavioral measures of risk ranging from 20% to upwards of 60%
[1–7]. Less is known, however, about the specific genes that
underlie such behaviors. Our goal is to make further steps toward
uncovering the potential genetic basis of risk taking by examining
the role of a specific polymorphism of the dopamine transporter
gene (SLC6A3; alternate symbol: DAT1). We examine its impact in
a widely used and potentially clinically relevant behavioral
measure of risk taking, the Balloon Analogue Risk Task (BART)
[8].
Behavioral, neuroimaging, and genetic evidence converge in
suggesting that genetic variability in dopaminergic systems is one
potential source of individual differences in risky choice (see [9],
for an overview). First, brain regions heavily innervated by
dopaminergic pathways, such as the striatum and dorsolateral
prefrontal cortex, have been shown to be implicated in decisions
under risk [10–11]. Second, variation in dopaminergic function
has been related to behavioral measures of risk taking [6,12] and
to personality traits that appear to accompany risk taking, such as
extraversion [13], impulsivity [14], and novelty seeking [15].
Finally, there are links between genetic variation in dopaminergic
genes and real-world risk-taking and addiction [16–17].
One candidate gene that may account for a portion of the
variation in risk-taking behavior is the dopamine transporter
gene (DAT1). It codes for a dopamine transporter protein that is
expressed abundantly in the striatum and is responsible for
regulating the dopaminergic release into the extracellular space
by recapturing dopamine into presynaptic terminals [18]. The
gene, which includes 15 exons, harbors a variable number of
tandem repeats (VNTR) polymorphism in its 39UTR. The 40-
bp VNTR element is repeated between 3 and 13 times but
occurs with greatest frequency in the 9- and 10-repeat forms
[19–21].
With regard to the functional effects of DAT1 on dopaminergic
function, a number of studies suggest that the DAT1 9-repeat
allele, relative to the 10-repeat allele, is associated with reduced
expression of dopamine transporter protein, resulting in relatively
increased extrasynaptic striatal dopamine levels in the former [22–
25]. Some studies, however, have reported the opposite direction
of effect [26–28], whereas others could not find any functional
effects of DAT1 [29–30]. Despite this mixed picture, on the whole
there is evidence for a role of DAT1 on reward processing that is
consistent with the thesis that the 9-repeat allele is associated with
increased striatal dopamine levels relative to the 10-repeat allele
[31–35]. Some results from other domains–for instance, investi-
gations of implicit learning [36] and cognitive control [37]–are
also in line with this effect.
How can people’s propensity to take risks be gauged in the
laboratory? Although numerous tasks have been designed to
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criticized for being too artificial and lacking external validity
[38]. One exception is the Balloon Analogue Risk Task
(BART). It embodies a naturalistic setting that has been shown
to be predictive of real-world risk-taking [8]. During the BART,
a balloon appears on a computer screen and participants are
asked to inflate it by pressing a button on the screen. Each
successful pump, simulated on the screen, results in a fixed
amount of money for this round. Participants are told that the
balloon will explode somewhere between the first pump and the
balloon filling up the screen. Should they pump until the
balloon bursts, they lose all rewards collected in this trial. Thus,
on each trial, participants have to decide when to stop pumping
and collect their rewards.
Risk taking as observed in the BART is correlated with (a) self-
reported measures of impulsivity and sensation seeking [8,39–40],
(b) self-reported real-world risk behaviors such as smoking [41–
42], unsafe sex [43], and risky drug use [8,44], and (c) another
behavioral measure of risk, the Iowa Gambling Task (once
behavior is decomposed through cognitive modeling) [45]. A
number of studies have demonstrated a significant contribution of
both frontal and striatal brain regions to risk behavior in the
BART. Concerning frontal contributions, functional imaging
studies have shown involvement of dorsal lateral prefrontal cortex
in the BART [46–48]. Also, an EEG study found that frontal
cortex activity was related to balloon bursts and that smaller
amplitudes in response to balloon bursts were associated with a
family history of alcohol problems [49], suggesting that heritable
factors related to sensitivity to losses may underlie both risk taking
in the BART and alcoholism. Another study showed that
transcranial direct current stimulation (tDCS) of the dorsolateral
prefrontal cortex leads to reduced pumping in the BART, thus
suggesting a causal role for frontal structures in regulating risk
taking [50]. Administering a version of the BART to rodents,
researchers found that temporary inactivation of a region
homologous to the human dorsolateral prefrontal cortex resulted
in increased variability in behavior and sub-optimal performance
in the BART but suggested that these frontal regions may exert
their influence ‘‘through direct regulation of specific striatal zones’’
[51]. In line with this conjecture, other findings suggest an
involvement of mesolimbic areas in risk taking in the BART. A
functional magnetic resonance imaging (fMRI) showed that risk
taking in the BART is associated with robust activation in the
ventral and dorsal striatum and anterior insula [46]. Other studies
found similar results with increased dorsal striatum activation
being linked to fewer pumps on the BART [47]. Also, a
comparison of Parkinson’s disease patients with and without
impulse control symptoms has showed that patients with impulse
control deficits showed significantly diminished BOLD activity in
the ventral striatum during engagement with the BART [48], thus
suggesting that striatal function is linked to risk taking in the
BART and impulsivity more generally.
Based on these results, in particular those suggesting an
important role of mesolimbic structures in the BART, we derived
two hypotheses concerning the role of dopaminergic function on
individual differences in risk taking in the BART. According to the
reduced-reward-sensitivity hypothesis, individual differences in risk
taking are caused by differences in sensitivity to rewards.
Specifically, it has been suggested that diminished striatal
dopamine levels, lowering reward sensitivity, can lead individuals
to seek more monetary or food rewards than people with higher
levels [52–53]. Consequently, in the BART, low reward sensitivity
could lead to increased pumping and thus greater risk taking–a
link that is consistent with decreased striatal activation being
associated with more pumping in the BART [47–48].
Alternatively, however, more risk taking in the BART may
not be due to reduced reward sensitivity but to more
indifference toward losses. Specifically, according to the
reduced-loss-sensitivity hypothesis, interindividual differences in risk
taking may be driven by differential sensitivity to those losses
that materialize once a balloon bursts [49]. Some researchers
have speculated that individual differences in loss aversion are
related to naturally occurring differences in dopaminergic
function [11]. To the extent that reduced levels of striatal
dopamine bring about reduced sensitivity to losses, individuals
with lower levels may react less strongly to balloon bursts
(losses) and, consequently, are able to tolerate more risk (i.e.,
more pumps). In sum, both hypotheses suggest that reduced
striatal dopamine availability plays a role in risk taking in the
BART. The diminished-reward sensitivity account attributes
more risk taking in the BART to reduced sensitivity to rewards.
The diminished-loss sensitivity account, in contrast, suggests a
direct link between more risk taking and reduced reactivity to
losses. Put simply, the former account portrays the risk takers as
those who gain less utility (satisfaction) from a unit of reward
than more risk-averse people; the latter account envisages the
risk takers as suffering from less disutility from a given loss than
more risk-averse people.
Our study examines the extent to which dopaminergic function
can modulate risk taking by linking a genetic polymorphism
(DAT1 VNTR) thought to modulate striatal dopamine function to
behavior in the BART. In the process, we will aim to determine
whether diminished reward or loss sensitivity accounts for a higher
propensity to take risks.
Methods
Participants
The study was approved by the ethics board of the canton Basel
(Ethikkomission beider Basel; www.ekkb.ch) and all participants
provided written informed consent before participating in the
study. Three hundred and sixty-nine adults participated in the
study. A power analysis was performed that suggested that
upwards of 300 participants would be needed to achieve
acceptable power (..80; e.g. t-test between roughly equal-sized
groups, a=.05, Cohen’s d=.25). Based on this analysis we aimed
to sample at least 300 participants and used the end of the
academic year as a stopping rule. As a consequence, data
collection spanned two consecutive academic years (2008/2009
and 2009–2010) and was stopped at the end of the second
academic year. Data were collected in Basel, Switzerland. The
majority of participants were students at the University of Basel, a
culturally diverse but predominantly Caucasian population.
Students were recruited through paper postings and the
psychology department’s online recruitment system. From the
available saliva samples, we were able to genotype a subset of
individuals (N=331). In addition, visual inspection of the data for
individual participants suggested that a few were not engaged in
the task as evidenced by pumping only once on every trial (the
minimum allowed), pumping only once after a few trials, or always
pumping until the balloon exploded on every trial. We excluded
participants in a principled manner by excluding 9 outliers whose
average number of pumps/adjusted pumps in the BART exceeded
63 SD of the group means. The overall pattern of results does not
change, however, when these individuals are included in the
analyses reported below. The final sample was composed of 322
participants (88 men; age range=18–55, M=23.8 years,
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problems or taking medication targeted at the dopaminergic
system.
Genetic Analysis
DNA was extracted from OrageneH DNA sample collection kits
(DNA Genotek Inc., Ontario, Canada). The 40-basepair VNTR
polymorphism in the 39 UTR of DAT1 was genotyped by PCR
using the following primers; forward: 59 -TGTGGTGTAGG-
GAACGGCCTGAG-39 reverse: 59 -CTTCCTGGAGGT-
CACGGCTCAAGG-39 using standard PCR settings. The PCR
products were visualized on a 2% agarose gel. The sizes of the
various repeat alleles were: 7-repeat (360 bp), 8-repeat (400 bp), 9-
repeat (440 bp), 10-repeat (480 bp), and 11-repeat (520 bp).
A minority of participants in our sample showed a 9-repeat/9-
repeat genotype (9/9; n=20). Most showed 9-repeat/10-repeat
(9/10; n=139) or 10-repeat/10-repeat (l0/10; n=167) genotypes,
and still another small group showed a 10-repeat/11-repeat
genotype (10/11; n=4). Genotypes were in Hardy-Weinberg
equilibrium (P=0.37). In our analysis, the following genotype
groups were compared: one group consisting of 9-repeat carriers (9
carriers; n=159) and another group consisting of non-carriers of
the 9-repeat allele (i.e., 10-repeat homozygotes and 11-repeat
carriers [10/10 and 11 carriers]; n=171).
Balloon Analogue Risk Task
Participants were faced with a series of 30 balloons (i.e., trials)
on the computer screen. In each trial, participants sequentially
pressed a button on the screen to inflate the balloon. The sequence
ended when a person chose to stop or the balloon exploded.
Participants did not complete practice trials or were informed
about the probability structure governing the balloons’ exploding.
For example, participants would have to learn from experience
that the probability of the balloon exploding increased with each
pump. However, participants were told that at some point each
balloon would burst and that this explosion could occur at any
point from the first pump to when the balloon had expanded to fill
the entire screen.
Each successful click increased the participants’ temporary
payoff but involved the risk that the balloon would explode.
Participants could decide when to stop pumping the balloon and
collect the payoff from their temporary account. If the balloon
exploded following a pump, the participant earned nothing for
that trial. If a person stopped inflating the balloon before it
exploded, the money earned was transferred to a permanent bank
depicted on the screen. Then a new balloon appeared and the next
trial began.
The point at which a balloon would burst was determined
randomly for each trial by drawing a number between 1 and 128
from a uniform distribution to represent the threshold number of
pumps at which the balloon would burst on that trial. The
resulting probability that a balloon will burst given a number of
pumps (pumps) can be described as follows [8]:
p(burst)~
1
128{pumps
ð1Þ
Equation 1 implies that the probability of a balloon bursting is a
function of the number of pumps. For example, the probability of
the balloon bursting is very small after pumping once, p(burst)=1/
(128–1)=1/127<.008. After 127 successful pumps, however, it is
certain that one more pump will cause the balloon to burst,
p(burst)=1/(128–127)=1/1=1. Participants received .01 Euro
for each successful pump (i.e., not causing an explosion). The
strategy promising the highest expected gain in the task is to pump
64 times in each of the 30 trials: this number represents the
average burst point and would result in an explosion on 15 of 30
trials on average.
Procedure
Participants first read and signed the informed consent form.
Then, participants completed a paper questionnaire concerning
their age, sex, and medical status, followed by computerized
testing which included the 30 BART trials, and finally provided a
saliva sample for genotyping.
Results
Table 1 presents summary measures of participants’ perfor-
mance in the BART, separately for the 9-repeat carriers and
the 10/10 and 11-repeat carriers. Across trials, the 9-repeat
carriers pumped significantly (p=0.031) fewer pumps and thus
earned less money than the 10/10 and 11-repeat carriers. The
effect size was small (Cohen’s d=0.24). Figure 1 depicts
participants’ payoff as a function of average number of pumps
as well as the mean number of pumps as a function of
genotype. It shows, as expected, that payoff increases non-
linearly as the average number of pumps approaches the
optimal value in the task (64 pumps; see task description above).
There is, of course, considerable variability in payoff for a given
number of pumps because of the probabilistic nature of bursts
in the BART. In addition, it shows that 10R/10R and 11R
tended to pump more than the 9R counterparts. Overall, these
results provide the first demonstration that there is a link, albeit
small in magnitude, between the DAT1 polymorphism and risk
taking in the BART, with 9-repeat carriers showing less risk
taking relative to 10/10 and 11-repeat carriers.
Having established this link, we can now ask whether increased
risk-taking (i.e., pumping) in the 10/10 and 11-repeat carriers is
brought about by diminished sensitivity to losses or by diminished
reward sensitivity. To discern between these two possibilities we
tested for effects of DAT1 genotype on risk adjustment after losses
(i.e., balloon bursts). The analysis’ rationale is that if increased risk
taking were related to insensitivity to losses, differential risk
adjustment following negative outcomes would emerge as a
function of genotype.
We employed a multilevel, mixed-effects modeling approach to
simultaneously model individual and group differences in pumping
frequency and sensitivity to losses (i.e., balloon explosions). Mixed-
effects models allow researchers to simultaneously consider
standard fixed-effects, but also covariates bound to the items
(e.g., trial type: burst vs. non-burst) or participants (e.g., genotype
grouping, age, sex). Crucially, these techniques allowed us to
model learning (trial) effects as well as local dependencies between
successive trials without requiring prior averaging across partic-
ipants or items that eliminates potentially informative variation in
the data and reduces statistical power [54].
We first conducted an initial screening of the amount of within-
person variability in the pumping data using the intraclass
correlation obtained from an unconditional means model in
which the residual variance was significant. The analysis indicated
that around one third of the total variance in pumping behavior
was located within persons (intraclass correlation=.28). Moreover,
the mean reliability was good (.92), suggesting it warranted
conducting a multilevel analysis. We then used the following set of
equations to model pumping behavior in the BART:
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39135Level 1 : Pumps~b0izb1i(trial)zb2i(burstt)zb3i(burstt{1)zrit
b0i~c00zc01(DAT1)zu0i
b1i~c10zu1i
b2i~c20zu2i
Level 2 : b3i~c30zu3i
In Level 1, pumping of participant i on trial t is a function of (a)
the intercept (b0i), (b) trial number (b1i; 1 to 30), (c) whether the
trial is a burst trial or not (b2i; 0=no burst, 1=burst), (d) whether
the previous trial was a burst trial or not (b3i; 0=no burst,
1=burst), (v) and the residual (rit). The equation thus captures for
each single individual a number of potential effects of interest. First
and foremost, the effect of learning: Participants typically pump less
than the optimal amount and increase their pumping with
experience (i.e., across trials) [8]. Second, the equation captures
differences between trials in which the balloon explodes and those
in which it does not as is commonly done by distinguishing
between average number of pumps and average number of pumps
in unexploded balloons (burstt) [8]. Finally, the equation accom-
modates the possibility that participants adjust their risk taking as a
function of the previous trial (burstt21). To our knowledge,
reactivity to burst trials has not been investigated in the past, so
our analysis represents an important pioneering contribution to
understanding trial-by-trial performance in the BART.
In the Level 2 equations, c00, c10, c20, and c30, represent mean
weights given to each factor represented in Level 1 and the
respective residuals, u0i,u 1i,u 2i,u 3i. In addition, we added DAT1
Figure 1. Left: Payoff in the Balloon Analogue Risk Task (in Euro) by mean number of pumps for 9-repeat carriers (9R) and 10-
repeat homozygotes and 11-repeat carriers (10R/10R). The black line represents the expected value of the respective mean number of
pumps.Right: Mean number of pumps and respective 95%CIs for 9-repeat carriers (9R) and 10-repeat homozygotes and 11-repeat carriers (10R/10R).
doi:10.1371/journal.pone.0039135.g001
Table 1. Means (SD) for demographic and Balloon Analogue Risk Task (BART) variables as a function of DAT1 Groups.
Variables 9-repeat carriers
10/10 and
11-repeat carriers x
2 or t statistic p-value Cohen’s d
n (males) 156 (44 =) 166 (44 =)– – –
Right Handedness 142 (91%) 149 (90%) 0.06 .81 –
Age 24.1 (6.9) 23.4 (5.2) 1.04 .30 0.12
Pumps 31.6 (11.0) 34.2 (10.8) 2.17 .031 0.24
Adjusted Pumps 35.7 (14.1) 38.9 (13.9) 2.01 .045 0.23
Bursts 9.3 (3.5) 9.9 (3.5) 1.56 .120 0.17
Payoff 7.0 (2.1) 7.5 (2.1) 1.96 .050 0.24
Note. Adjusted Pumps=Pumps in unexploded balloons.
doi:10.1371/journal.pone.0039135.t001
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predictor at the level of the intercept to capture mean level
differences in pumping as a function of DAT1 genotype (Model 1).
Crucially, we also tested a number of additional models that
considered additional effects of DAT1, including an interaction
between DAT1 and the adjustment of risk as a function of the
previous trial (Model 2: b3i=c30+c31 (DAT1)+u3i). The rationale
for including an effect of DAT1 at this level is that observing an
effect of genotype would suggest that DAT1 moderates risk taking
through differences in reactivity to losses, as suggested by the
diminished-loss-sensitivity hypothesis. We also considered further
interactions between DAT1 and trial to account for possible
differences in learning rates as a function of genotype (Model 3:
b1i=c10+c11 (DAT1)+u1i), and bursts (Model 4: b2i=c20+c21
(DAT1)+u2i). Finally, we considered a model that included the
available control variables (age, sex, handedness; Model 5). We
estimated parameters for all models using the MCMCglmm
package for R [54], and used the chi-squared distributed Deviance
Information Criterion (DIC) as a measure of fit [55,56].
As expected, Model 1 (DIC=81718), provided a better fit to
participants’ data relative to a baseline model (unconditional
means model; DIC=82202), DDIC=81718–82202=2484,
df=13, p,.001. In turn, Model 2, which included the possibility
that DAT1 polymorphism moderates the impact of a loss in the
previous trial, did not prove considerably better than Model 1,
DDIC=21.4, df=1,p=.24. This finding suggests that DAT1 does
not moderate reactivity to losses. The other models also did not
prove better than Model 1, Model 3, DDIC=20.4, df=1,p=.53,
Model 4, DDIC=21.1, df=1,p=.29. Finally, controlling for age,
sex, and handedness, Model 5, DDIC=5.8, df=3,p=.12, did not
change the pattern of results already identified in Model 1.
The parameter estimates, the respective confidence intervals,
and p values for the fixed effects for Model 1 parameters are given
in Table 2 and the main effect of genotype is depicted in Figure 2.
The results indicate that our participants showed the typical
behavioral pattern found in previous studies: with, on average, 33
pumps given initially they remained far below the optimal 64
pumps [8]. Nevertheless, there was evidence of learning with
participants increasing their pumping by, on average, one pump
every 5 trials (leading to an average of 39 pumps in the final of 30
rounds). In addition, there was an effect of burst, with about 11
fewer pumps being made in those trials in which balloons exploded
relative to those in which it did not. Furthermore, a burst in the
previous trial (burstt21) affected the subsequent trial, with, on
average, 4 fewer pumps in the trial following a burst trial. This
result is the first demonstration that participants adjust their
pumping behavior on the basis of bursts on a trial-by-trial basis.
Finally, there was an effect of DAT1, with 10/10 and 11-repeat
carriers engaging in between 2 to 4 pumps more per balloon
relative to 9-repeat carriers.
Discussion
Our findings suggest that DAT1 polymorphism is associated
with risk taking in a widely used and potentially clinically relevant
task, the Balloon Analogue Risk Task [8]. Specifically, carriers of
DAT1 alleles, which presumably result in lower striatal dopamine
availability (10-repeat homozygotes and 11-repeat carriers),
engaged in more risk taking relative to those with higher striatal
dopamine availability (9-repeat allele carriers). Based on our
analysis of the carriers of different alleles to losses, we conclude
that more risk taking in the BART appears to be associated with
diminished reward sensitivity but not sensitivity to losses.
Specifically, individuals with lower striatal dopamine availability
tend to seek higher rewards (and therefore tolerate more risk). This
notion has also been proposed to explain individual differences in
gambling [52] and weight-gain [53]. For example, genetic risk for
reduced signaling of dopamine-based reward circuitry and
consequently low striatal response to food intake (reward) predicts
future weight gain [57].
An alternative interpretation of our findings is that lower
striatal dopaminergic availability negatively influence cognitive
control processes, such as the ability to inhibit pumping in the
BART. Our data cannot exclude this alternative explanation
but the pattern of results regarding the link between DAT1 and
cognitive control is mixed [37,58], thus leading us to favor the
diminished-reward sensitivity hypothesis. Future work that links
DAT1 status to both BART and cognitive control measures
such a Go/NoGo performance could test between these two
alternative explanations.
Figure 2. Average pumps on self-terminated trials as a function
of trial number for 9-repeat carriers (9R; dashed line) and 10-
repeat homozygotes and 11-repeat carriers (10R/10R & 11R;
solid line), as estimated from multilevel modeling (see text).
The diameter of the circles is proportional to the number of participants
that gave the respective number of pumps on that trial.
doi:10.1371/journal.pone.0039135.g002
Table 2. Parameter Estimates from the Multilevel Regression
Modeling for Model 1 (see text).
Fixed Effects Coefficient 295% CI +95% CI p
Intercept (c00) 33.39 32.51 34.35 ,.001
Trial (c10) 0.19 0.11 0.26 ,.001
Burstt (c20) 211.73 212.43 211.02 ,.001
Burstt–1 (c30) 24.10 25.10 23.16 ,.001
DAT1 (c01) 2.82 1.63 3.97 ,.001
doi:10.1371/journal.pone.0039135.t002
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addressed in the future. First, the genetic association reported
herein has to be replicated in independent studies and is therefore
considered to be preliminary. Second, we focused on a single
genetic polymorphism, DAT1 VNTR, which is only one of several
polymorphisms known to regulate striatal dopamine levels [9].
Moreover, there are important frontal contributions to behavior in
the BART [46–50], such as those from the dorso-lateral prefrontal
cortex where the dopamine transporter is not significantly
expressed. Consequently, future investigations should try to assess
a more comprehensive number of polymorphisms related to
frontostriatal function, including COMT, DARPP-32, DAT1,
DRD2, and DRD4, among others [9]. Assessing multiple
polymorphisms will require making assumptions about possible
interactions between genes [34]. Nevertheless, establishing such
profiles could prove fruitful in combination with imaging methods
to observe to what extent brain activation varies as a function of
genetic makeup [33]. Alternatively, future research could employ a
genome-wide association study-design to identify possible new
molecular pathways associated with risk taking. However, such
studies must include larger samples (n.1000). One important
advantage of conducting such large-scale studies is the possibility
of considering theoretically meaningful assessments of less frequent
genotype groups, such as the infrequent 9-repeat-homozygous
group for DAT1 that represented a minority in our sample, and
were thus collapsed with the 9-repeat-carriers to ensure acceptable
statistical power in our analyses.
Finally, one may also consider a change to our probabilistic
implementation of the BART. Because of its random probability
structure, the BART will produce considerable differences inpayoff
notwithstandingsimilarpumpingbehavior.Thisstructuralfeatureof
the task contributes to its realism but it also increases random
variability in individuals’ payoff. Consequently, one may want to
further study the impact of dopaminergic function on risk taking by
providing all individuals with the same set of bursting points across
trials.
Inconclusion,ourfindingssuggestthatageneticpolymorphismof
thedopaminetransportergene,DAT1,islinkedtorisktakinginatask
that has been shown to be associated with self-reported clinical risk
taking.Moreover,ourresultssuggestthatthemechanismunderlying
this association is diminished sensitivity to reward (and not
diminished sensitivity to losses). Finally, our results support the
notion that the behavioral genetic approach can be helpful in
uncovering the basis ofindividual differences inrisk taking.
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